🚀 Akero Therapeutics is making waves in the race to treat non-alcoholic steatohepatitis (NASH) with its breakthrough therapy, efruxifermin! 🎯 Analyst Eliana Merle sets a $83 price target, implying a 73% gain in the next 12 months.

Key points:

- Efruxifermin received Breakthrough Therapy Designation from the FDA in December.

- NASH affects 5% of US adults, with no FDA-approved therapy available.

- Efruxifermin could be the first FGF21 to market, potentially leading NASH treatments in development.

- NASH market opportunity worth over $20 billion.

Akero's efruxifermin therapy could be a game-changer, targeting NASH patients with fibrosis and even cirrhosis. Keep an eye on this promising development! 👀💡